Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status Prescription
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 60505-3250; 53873-075; 53873-073; 55773-0589; 49702-204; 49702-203; 50742-623; 65015-701; 68180-603; 50742-624; 65862-259; 53873-074; 54838-566; 31722-752; 64380-711; 49702-205; 31722-001; 70159-001; 52482-003; 64380-710; 31722-753; 68554-0043; 65862-026; 33342-001; 69097-167; 70518-3267; 57237-274; 65015-756; 70518-2067; 70518-2070; 67835-0017; 0173-0662; 53104-7538; 60687-362; 0173-0663; 60505-3252; 53104-7677; 65862-025; 68180-602; 65862-055; 68554-0016; 66993-478; 31722-754; 65862-577; 69097-166; 42385-714; 33342-002; 60505-3251; 60429-354; 60429-353; 0904-6583
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatitis B11.05.06.002; 09.01.09.0030.238851%
Hepatitis B surface antigen positive13.08.03.0010.018551%Not Available
Hepatitis C11.05.06.004; 09.01.09.0050.013914%Not Available
Hepatocellular injury09.01.07.0080.006957%Not Available
Hepatomegaly09.01.05.001--Not Available
Hepatorenal syndrome20.01.03.012; 09.01.03.0070.001210%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.025508%Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
Hyperaesthesia17.02.06.004--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperlactacidaemia14.01.01.006--Not Available
Hyperparathyroidism05.04.01.0010.004638%
Hyperphosphataemia14.04.03.0070.011595%
Hypersensitivity10.01.03.003--
Hypertriglyceridaemia14.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypocalcaemia14.04.01.0040.004638%
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypophosphataemia14.04.03.0010.009276%
Hypospadias21.15.01.003; 20.07.04.001; 03.03.01.0050.004638%Not Available
Hypotension24.06.03.002--
Hypouricaemia14.09.01.0060.004638%Not Available
Hypoxia22.02.02.003--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.0020.020870%Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages